AMGN vs GILD stock comparison
Amgen vs. Gilead Sciences · data as of November 13, 2026
Amgen (AMGN) has a market value of about $251.9B, Gilead Sciences (GILD) about $208.5B. Over their latest twelve months Amgen had revenue of $38.9B and Gilead Sciences $31.0B.
On our five checks Gilead Sciences scores higher: 2.8 out of 5 (average) against 2.4 (weak).
By area, the stronger company is Gilead Sciences on value; Amgen on future growth; Gilead Sciences on track record; Gilead Sciences on financial health.
Amgen leads on 11 of the compared lines and Gilead Sciences on 11.
Side by side
| AMGN | GILD | |
|---|---|---|
| Size and price | ||
| Market cap | $251.9B | $208.5B |
| Share price | $465.67 | $168.08 |
| Score | ||
| Overall score (of 5) | 2.4 | 2.8 |
| Value | 0 | 1 |
| Future growth | 3 | 2 |
| Track record | 3 | 4 |
| Financial health | 2 | 3 |
| Shareholder returns | 4 | 4 |
| Valuation | ||
| P/E (TTM) | 27.0 | — |
| Forward P/E | 19.5 | 20.3 |
| Price / free cash flow | 26.3 | 15.1 |
| Price / sales | 6.5 | 6.7 |
| EV / EBITDA | 17.1 | 559.5 |
| PEG | 9.18 | — |
| DCF value vs. price | −26% | −35% |
| Business | ||
| Revenue | $38.9B | $31.0B |
| Net income | $9.4B | -$3.9B |
| Free cash flow | $9.6B | $13.8B |
| Net margin | 24.1% | -12.5% |
| Gross margin (5-yr avg.) | 69.9% | 77.6% |
| ROIC (5-yr avg.) | 13.5% | 12.2% |
| Growth | ||
| Revenue growth (1 yr) | 10.0% | 2.4% |
| Revenue growth (5 yrs, per year) | 7.6% | 3.6% |
| EPS growth (5 yrs, per year) | 2.9% | 132.4% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$40.8B | -$19.8B |
| Dividend yield | 2.16% | 1.95% |
| Shareholder yield | 2.2% | 2.9% |
| Analysts | ||
| Upside to average target | −7% | +4% |
| Consensus rating | Hold | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: AMGN TTM to September 30, 2026, GILD TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Amgen or Gilead Sciences?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Gilead Sciences scores 2.8 out of 5 and Amgen 2.4; the table shows where each one is stronger.
Which grows faster, Amgen or Gilead Sciences?
Over five years Amgen grew revenue about 7.6% a year and Gilead Sciences about 3.6% a year.
Which pays a higher dividend?
Amgen yields 2.16% and Gilead Sciences 1.95%.
Full Amgen analysis → Full Gilead Sciences analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.